- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01773304
Acute Effects of Dairy and Meat Proteins on Bone Metabolism and Metabolic Profile (MEDA)
22 mars 2013 uppdaterad av: AAstrup, University of Copenhagen
Acute Effects of Dairy and Meat Proteins on Bone Metabolism and Metabolic Profile in Urine and Plasma in Overweight Adults
The purpose of this randomized, controlled, cross over single meal study is to investigate the metabolic effects of a breakfast rich in dairy proteins and to determine biomarkers for their intake.
The results from this project will increase our knowledge about nutritional value of dairy proteins, which is necessary to decide whether dairy products can be recommended for prevention of weight related bone loss.
Studieöversikt
Status
Avslutad
Betingelser
Intervention / Behandling
Studietyp
Interventionell
Inskrivning (Faktisk)
17
Fas
- Inte tillämpbar
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studieorter
-
-
Frederiksberg C
-
Copenhagen, Frederiksberg C, Danmark, 1958
- Department of Human Nutrition, University of Copenhagen
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
18 år till 50 år (Vuxen)
Tar emot friska volontärer
Nej
Kön som är behöriga för studier
Allt
Beskrivning
Inclusion Criteria:
- Healthy males and females between 18 and 50 years
- BMI 25-40
Exclusion Criteria:
- Physical activity more than 10 hours weekly
- Smoking
- Diagnosed osteoporosis in at least one parent
- Dietary supplements and vitamin pills (during the study and 2 months before the start)
- Vegetarians and vegans
- Lactose intolerant
- Women who are pregnant, breastfeeding or post-menstrual
- Regular intake of medication
- Chronic diseases (including osteoporosis, cancer, diabetes, cardiovascular disease and mental disorders)
- Participation in other clinical trials that could affect the test results
- Donation of blod within 3 months before intervention start
- Hypersensitivity to paraaminobenzoic acid (PABA)
- Not able to comply with the procedures established by the Protocol
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Förebyggande
- Tilldelning: Randomiserad
- Interventionsmodell: Crossover tilldelning
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Meal rich in dairy protein
|
Test meals with different protein types (dairy versus meat)
|
|
Experimentell: Meal rich in meat protein
|
Test meals with different protein types (dairy versus meat)
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
serum C-terminal carboxy-terminal collagen crosslinks (CTX)
Tidsram: at 0, 30, 60, 120, 180 and 240 min at both visits
|
at 0, 30, 60, 120, 180 and 240 min at both visits
|
|
urine C-terminal carboxy-terminal collagen
Tidsram: baseline 24-h urine samples and 24-h urine samples after the meal test at both visits
|
baseline 24-h urine samples and 24-h urine samples after the meal test at both visits
|
|
serum osteocalcin (sOC)
Tidsram: at 0, 30, 60, 120, 180 and 240 min at both visits
|
at 0, 30, 60, 120, 180 and 240 min at both visits
|
|
serum tartrate-resistant acid phosphatase (s-TRAP)
Tidsram: at 0, 30, 60, 120, 180 and 240 min at both visits
|
at 0, 30, 60, 120, 180 and 240 min at both visits
|
|
urine deoxypyridinoline crosslink (uDPD)
Tidsram: baseline 24-h urine samples and 24-h urine samples after the meal test at both visits
|
baseline 24-h urine samples and 24-h urine samples after the meal test at both visits
|
|
plasma metabolites for metabolomics analyses
Tidsram: at 0, 30, 60, 120, 180 and 240 min at both visits
|
at 0, 30, 60, 120, 180 and 240 min at both visits
|
|
urine metabolites for metabolomics analyses
Tidsram: baseline 24-h urine samples, 24-h urine samples after the meal test, urine samples at 2-h and 4-h after the meal test and urine samples from 4-h to 24-h, all at both visits
|
baseline 24-h urine samples, 24-h urine samples after the meal test, urine samples at 2-h and 4-h after the meal test and urine samples from 4-h to 24-h, all at both visits
|
Sekundära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
serum insulin-growth factor-1 (IGF-1)
Tidsram: at 0, 30, 60, 120, 180 and 240 min at both visits
|
at 0, 30, 60, 120, 180 and 240 min at both visits
|
|
serum insulin-growth factor binding-protein-3 (IGFBP-3)
Tidsram: at 0, 30, 60, 120, 180 and 240 min at both visits
|
at 0, 30, 60, 120, 180 and 240 min at both visits
|
|
serum insulin
Tidsram: at 0, 30, 60, 120, 180 and 240 min at both visits
|
at 0, 30, 60, 120, 180 and 240 min at both visits
|
|
serum glucose
Tidsram: at 0, 30, 60, 120, 180 and 240 min at both visits
|
at 0, 30, 60, 120, 180 and 240 min at both visits
|
|
serum glukagon-like peptide-1 (GLP-1)
Tidsram: at 0, 30, 60, 120, 180 and 240 min at both visits
|
at 0, 30, 60, 120, 180 and 240 min at both visits
|
|
urinary PABA
Tidsram: baseline 24-h urine samples and 24-h urine samples after the meal test at both visits
|
baseline 24-h urine samples and 24-h urine samples after the meal test at both visits
|
|
urinary creatinin
Tidsram: baseline 24-h urine samples and 24-h urine samples after the meal test at both visits
|
baseline 24-h urine samples and 24-h urine samples after the meal test at both visits
|
|
urinary biobank
Tidsram: baseline 24-h urine samples and 24-h urine samples after the meal test at both visits
|
baseline 24-h urine samples and 24-h urine samples after the meal test at both visits
|
|
plasma biobank
Tidsram: at 0, 30, 60, 90, 120, 180 and 240 min at both visits
|
at 0, 30, 60, 90, 120, 180 and 240 min at both visits
|
Andra resultatmått
Resultatmått |
Tidsram |
|---|---|
|
weight
Tidsram: at baseline at both visits
|
at baseline at both visits
|
|
height
Tidsram: at baseline at the first visit
|
at baseline at the first visit
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Samarbetspartners
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart
1 december 2012
Primärt slutförande (Faktisk)
1 februari 2013
Avslutad studie (Faktisk)
1 februari 2013
Studieregistreringsdatum
Först inskickad
15 januari 2013
Först inskickad som uppfyllde QC-kriterierna
22 januari 2013
Första postat (Uppskatta)
23 januari 2013
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
25 mars 2013
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
22 mars 2013
Senast verifierad
1 mars 2013
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- M210
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .